Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Shares of Biogen Inc. slipped 5.04% to $169.31 Wednesday, on what proved to be an all-around grim trading session for the ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Biogen Inc. has signed a lease for a new global headquarters at Kendall Common in Cambridge, Massachusetts, as part of a multi-year real estate optimization plan aimed at modernizing its facilities ...

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Biogen has invested ...

Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop novel RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics will utilize ...

Biogen Inc. ( BIIB) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 4:30 PM EST ...

CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s ...

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...

Biogen Inc. closed 1.38% below its 52-week high of $185.17, which the company reached on November 24th.

Better-than-expected Alzheimer's disease treatment sales and a quarterly beat were not enough to offset below-consensus EPS outlook Biogen Inc.'s stock (BIIB) tumbled 7% Wednesday, after the biotech ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...